Today's typical biotech tour may not include a swing through the lab — because there isn’t one. Chief executives now brag about the cost savings and flexibility of outsourcing everything from the design of a new drug to supervision of clinical trials to eventual manufacturing.
“The only lab equipment we have here is the sink in the restroom,” says Tom Hughes, chief executive of Zafgen.
Is Boston's Chamber of Commerce relevant to the city's startup community? Hardly. In Scott Kirsner's Innovation Economy column this week, he offers five ways that the new president of the chamber, James E. Rooney, can make the Chamber matter more, not just to entrepreneurs, but to everyone in Boston.